VIDEO: AbbVie presents emerging data on Rinvoq, Skyrizi clinical trials
Click Here to Manage Email Alerts
In a video exclusive, Remo Panaccione, MD, University of Calgary, outlined new therapeutic data for the treatment of patients with inflammatory bowel diseases at the 16th Congress of European Crohn’s and Colitis Organisation.
Highlighted studies included the U-ACHIEVE and U-ACCOMPLISH phase 3 therapeutic induction studies in which researchers evaluated the safety and efficacy of Rinvoq (upadacitinib) for the treatment of patients with moderate to severe ulcerative colitis. Primary reported endpoints were clinical, endoscopic and histologic outcomes after 8-weeks of treatment.
Panaccione also reported on the ADVANCE and MOTIVATE global phase 3 therapeutic induction studies of Skyrizi (risankizumab) for the treatment of patients with moderate to severe Crohn’s disease. Investigators examined clinical remission and response as well as improved endoscopic outcomes at week 12; in an additional study, investigators evaluated the impact of therapeutic induction on patient-reported outcomes.
“I anticipate great things from the [Rinvoq, Skyrizi] maintenance trials,” Panaccione concluded. “Hopefully, both of these drugs will make an impact, not only in our clinical practice, but to the lives of patients if and when they get approved for use.”
Collapse
Panaccione R, et al. Abstract OP23. Presented at: Congress of European Crohn’s and Colitis Organisation; July 8-10 (virtual meeting).
Panaccione R, et al. Abstract OP24. Presented at: Congress of European Crohn’s and Colitis Organisation; July 8-10 (virtual meeting).
Panaccione R, et al. Abstract OP26. Presented at: Congress of European Crohn’s and Colitis Organisation; July 8-10 (virtual meeting).
Panaccione R, et al. Abstract DOP88. Presented at: Congress of European Crohn’s and Colitis Organisation; July 8-10 (virtual meeting).
Panaccione R, et al. Abstract OP36. Presented at: Congress of European Crohn’s and Colitis Organisation; July 8-10 (virtual meeting).
Read more about
Click Here to Manage Email Alerts